Skip to main content
Premium Trial:

Request an Annual Quote

Vermillion Receives ISO Certification

NEW YORK (GenomeWeb) – Vermillion said after the close of the market on Thursday that the British Standards Institution has awarded the company ISO 13485:2003 certification for its quality management system. 

ISO 13485:2003 is the internationally recognized quality standard for medical devices and diagnostics, and is based on quality management principles — such as customer focus, management, internal processes, and external relationships — that enhance organization performance, Vermillion said. 

Vermillion President and CEO Valerie Palmieri said in a statement that the certification is a building block for the company's planned international expansion. 

Vermillion markets the OVA1 ovarian cancer test. It also is working on its next-generation proteomics-based OVA2 ovarian cancer test, which includes three of the original five OVA1 biomarkers along with two new protein markers.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.